Literature DB >> 17460589

Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy.

Yasuhiko Hirami1, Akitaka Tsujikawa, Atsushi Otani, Yuko Yodoi, Hiroko Aikawa, Michiko Mandai, Nagahisa Yoshimura.   

Abstract

PURPOSE: To evaluate the clinical features and risk factors of hemorrhagic complications in eyes with polypoidal choroidal vasculopathy (PCV) after photodynamic therapy (PDT).
METHODS: We retrospectively reviewed data for 91 consecutive eyes of 85 patients who underwent PDT for the treatment of PCV. The diagnosis of PCV was based on indocyanine green angiographic findings, showing a branching vascular network terminating in polypoidal swelling. The greatest linear dimension included all polypoidal lesions, leaking vascular network, and type 2 choroidal neovascularization.
RESULTS: During the follow-up period after PDT, postoperative subretinal hemorrhage was seen in 28 (30.8%) of 91 eyes. In 22 (78.6%) of these 28 eyes, subretinal hemorrhage was absorbed without treatment. In 6 eyes (21.4%), however, bleeding resulted in vitreous hemorrhage, and 2 eyes underwent pars plana vitrectomy. Although visual acuity was maintained or increased in 18 (81.8%) of 22 eyes with subretinal hemorrhage alone, it decreased significantly in 3 (50.0%) of 6 eyes with postoperative vitreous hemorrhage. Various systemic diseases and medication with an anticoagulant had no correlation with these hemorrhagic complications. Laser irradiation spot size for PDT was significantly larger in eyes with postoperative vitreous hemorrhage (P = 0.017) than in those without.
CONCLUSION: Subretinal hemorrhage after PDT can be a common complication in patients with PCV and may have a minor effect on visual outcome. However, postoperative hemorrhage is occasionally so massive that it leads to vitreous hemorrhage and poor visual prognosis. When considering PDT for eyes with a large PCV lesion, ophthalmologists should be aware of the risk of serious hemorrhagic complications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460589     DOI: 10.1097/01.iae.0000233647.78726.46

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  54 in total

1.  Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.

Authors:  Akitaka Tsujikawa; Sotaro Ooto; Kenji Yamashiro; Hiroshi Tamura; Atsushi Otani; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

2.  Reply to the letter to the editor: genetic influence on visual outcomes of polypoidal choroidal vasculopathy.

Authors:  Masayuki Hata; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-04       Impact factor: 3.117

3.  Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy.

Authors:  M Inoue; A Arakawa; S Yamane; K Kadonosono
Journal:  Eye (Lond)       Date:  2013-08-23       Impact factor: 3.775

4.  Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.

Authors:  Ryusaburo Mori; Mitsuko Yuzawa; Zeon Lee; Miho Haruyama; Eriko Akaza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-30       Impact factor: 3.117

5.  Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy: a 2-year result and systematic review.

Authors:  Meng Zhao; Hai-Ying Zhou; Jun Xu; Feng Zhang; Wen-Bin Wei; Ning-Pu Liu
Journal:  Int J Ophthalmol       Date:  2017-03-18       Impact factor: 1.779

6.  One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy.

Authors:  Mio Hosokawa; Yuki Morizane; Masayuki Hirano; Shuhei Kimura; Fumiaki Kumase; Yusuke Shiode; Shinichiro Doi; Shinji Toshima; Mika Hosogi; Atsushi Fujiwara; Toshiharu Mitsuhashi; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2016-12-07       Impact factor: 2.447

7.  Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy.

Authors:  Isao Nakata; Akitaka Tsujikawa; Kenji Yamashiro; Atsushi Otani; Sotaro Ooto; Yumiko Akagi-Kurashige; Naoko Ueda-Arakawa; Daisuke Iwama; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-25       Impact factor: 3.117

8.  Two-year visual outcome of polypoidal choroidal vasculopathy treated with photodynamic therapy combined with intravitreal injections of ranibizumab.

Authors:  Masayuki Hata; Akitaka Tsujikawa; Masahiro Miyake; Kenji Yamashiro; Sotaro Ooto; Akio Oishi; Isao Nakata; Ayako Takahashi; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-30       Impact factor: 3.117

9.  Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis.

Authors:  Long-Hui Han; Li-Fei Yuan; Xu Liang; Xin Jia; Ming-Lian Zhang
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

10.  Clinical features, management and visual outcome of polypoidal choroidal vasculopathy in Indian patients.

Authors:  Giridhar Anantharaman; Gudapati Ramkumar; Mahesh Gopalakrishnan; Alpesh Rajput
Journal:  Indian J Ophthalmol       Date:  2010 Sep-Oct       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.